Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial

Filip Málek,Piotr Gajewski,Robert Zymliński,Dariusz Janczak,Mariusz Chabowski,Marat Fudim,Tomas Martinca,Petr Neužil,Jan Biegus,Martin Mates,Andreas Krüger,Ivo Skalský,Anisha Bapna,Zoar J. Engelman,Piotr P. Ponikowski

DOI: https://doi.org/10.1002/ejhf.2209

2021-07-16

European Journal of Heart Failure

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>Inappropriate control of blood volume redistribution may be a mechanism responsible for exercise intolerance in heart failure with preserved ejection fraction (HFpEF). We propose to address this underlying pathophysiology with selective blockade of sympathetic signaling to the splanchnic circulation by surgical ablation of the right greater splanchnic nerve (GSN).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and Results</h3><p>In a single‐arm, prospective, 2‐center trial, 10 patients with HFpEF (50% male, 70±3 years) all with NYHA class III, left ventricular ejection fraction &gt; 40%, pulmonary capillary wedge pressure (PCWP) ≥ 15 mmHg at rest or ≥ 25 mmHg with supine cycle ergometry, underwent ablation of the right GSN via thoracoscopic surgery. Patients were evaluated at baseline, 1, 3, 6 and 12 months after the procedure. The primary endpoint was a reduction in exercise PCWP at 3 months. There were no adverse events related to the blockade of the nerve during 12 months follow‐up but 3 patients had significant peri‐procedural adverse events related to surgical procedure itself. At 3 months post GSN ablation, patients demonstrated a reduction in 20 watts exercise PCWP when compared to baseline ‐4.5 mmHg (95% confidence interval [CI] ‐14 to ‐2; p=0.0059), which carried over to peak exercise ‐5 mmHg (95% CI ‐11 to 0; p=0.016). At 12 months improvements were seen in NYHA class (3 [3, 3] vs. 2 [1, 2]; p=0.0039), quality of life assessed with the Minnesota Living with Heart Failure Questionnaire (60 [51, 71] vs. 22 [16, 27]; p=0.0039).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>These results demonstrate, in this first‐in‐human study, that GSN ablation in HFpEF is feasible, with a suggestion of reduced cardiac filling pressure during exercise, improved quality of life and exercise capacity.</p><p>This article is protected by copyright. All rights reserved.</p></section>

cardiac & cardiovascular systems